Rezolute (RZLT) said Wednesday that the Independent Data Monitoring Committee has recommended continuing the biotechnology company's late-stage study to treat patients with congenital hyperinsulinism without increasing the sample size.
The study is designed to evaluate the efficacy and safety of ersodetug in patients with congenital hyperinsulinism who have poorly controlled hypoglycemia, the company said.
Rezolute said enrollment for the study is on track to be completed in May, with topline data due in December.
Shares of Rezolute were up 23% in recent premarket activity.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。